BerGenBio Nyheter

BioBull
BGBIO 01.10.2021 kl 16:48 525184

PhD : Rolf A. Brekken

https://www.utsouthwestern.edu/labs/brekken/research/

Flink forsker som også har trua på BerGenBio…

BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021

Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online from 10-14 November 2021.

Abstract titles have been announced online at the SITC website. Details of the presentation are below.

Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

Author: Rolf A. Brekken

Redigert 17.01.2022 kl 08:07 Du må logge inn for å svare
Carrera
30.03.2022 kl 19:32 10486

«Vi snakkes på seksti-kroner» Blir borte en stund du da?
BioBull
31.03.2022 kl 11:37 10135

En gledens dag for BerGenBio optimister.


CNBC :
Biden warns Congress that U.S. won't have enough Covid vaccines without more aid

https://www.cnbc.com/2022/03/30/biden-warns-us-wont-have-enough-covid-vaccine-shots-without-aid-from-congress.html?__source=iosappshare%7Cnet.whatsapp.WhatsApp.ShareExtension

President Joe Biden said the U.S. has enough vaccine supply to ensure people ages 50 and older can get their fourth doses. The Centers for Disease Control and Prevention cleared fourth shots for these people Tuesday.
However, Biden said the U.S. will not have enough supply to guarantee free access to vaccines for all Americans in the fall.
The president also unveiled a new government website, covid.gov, where Americans can find out where they can obtain masks, tests, vaccines and treatments.

Usa mangel på vaksiner gjør det mulig for BerGenBio å ta innersvingen på alle de store farmasøytiske produsentene av Covid-19 vaksiner.

Bare vent å se når de små en dags pillene distribueres i milliarder til en brøk del av prisen på Covid vaksiner.

Intet behov for personell
intet behov for fryselager

En Bemcentinib pille om dagen er nok - svelg og slipp alvorlige symptomer.

Helt Genialt
Helt BerGenBio

Forum forum
31.03.2022 kl 12:35 10040

Det meste som skriver rundt Covid om dagen er at dette ikke er over. Effekten etter Covidsmitte er grusom, og fortsatt er mye ukjent. I dagens aviser ser man at det er skrevet at man ikke vet om det er omikron eller delta varianter som kommer til høsten. De antar at befolkningen har høyere motstand mot omikron. Det er en vill spekulasjon gitt at man ser at det er store andeler av smittede som både har trippel dose og dobbel + første type omikron. Mange rapporterer også at de blir vesentlig fysisk svekket en god stund etter dose 3. Derfor vil motstanden mot nye doser øke i befolkningen og man må finne løsninger som bemcentinib for å hjelpe folk som er syke.
kongkveite
04.04.2022 kl 21:00 8372

Faen! Har short pakket begynt å dekke inn ?
Noe i emning? Kan det bli god stemning ?
BioBull
05.04.2022 kl 10:15 8158

POSITION HOLDER SHORT POSITION SHORT
👍… 21.20 blir også et viktig trendbrudd for tekniske tradere…


Arrowstreet spør nok etter større BGBIO poster hos meglerne i London nå,- iflg velinformerte kilder hos JPM…

PERCENT POSITION DATE (DD.MM.YYYY)
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 531 662 0,59% 01.04.2022
SUM 531 662 0,59%
Redigert 05.04.2022 kl 10:18 Du må logge inn for å svare
klaesp
05.04.2022 kl 14:38 8140

Her er det bare å holde på aksjene:)
Hjelpalaus
05.04.2022 kl 22:58 7882

Hyggelig å endelig se grønne tall på investeringen i BGBIO. Riktignok bare 5% ,men den kan fort bli 50% før sommeren
BioBull
07.04.2022 kl 14:08 7291

BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021

Bergen, Norway – 7 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2021 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).

The Annual Report for 2021 and ESEF file are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/

StockWizard
10.04.2022 kl 16:29 6771

Rykter om melding i morgen!
klaesp
10.04.2022 kl 19:04 6674

HVORFOR akkurat i morgen, og ikke tirsdag?
StockWizard
10.04.2022 kl 19:35 6723

Kun 12 timer igjen!
Vent og se!
Redigert 10.04.2022 kl 19:37 Du må logge inn for å svare
klaesp
10.04.2022 kl 20:01 6720

Spennende 👍
BioBull
11.04.2022 kl 07:07 6495


Hanni Gabra’s etterfølger er klar :
En utnevnelse som blir lagt merke til…

https://m.marketscreener.com/quote/stock/BERGENBIO-ASA-34541487/news/BerGenBio-strengthens-its-leadership-team-with-appointment-of-Cristina-Oliva-as-Chief-Medical-Office-40018301/




BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

Bergen, Norway, 11 April 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the appointment of Cristina Oliva, MD as Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research Organizations (CROs). Most recently Cristina was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd, where she led the development of decentralized trials and established and led the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA, Cristina held senior positions leading oncology development programs for Nordic Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “I’m delighted to welcome Cristina as our new Chief Medical Officer. Cristina’s leadership experience within oncology drug development across big pharma, biotech and CRO environments will be instrumental in executing BerGenBio’s development strategy for our AXL inhibitor programs, including our most advanced program bemcentinib, currently in phase II trials.”

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD, commented: “BerGenBio is on the frontier of developing novel, highly selective AXL inhibitors for the treatment of severe diseases such as oncology and respiratory infections. I’m very excited to join BerGenBio at this critical phase and look forward to working with the senior leadership team to help further advance its AXL inhibitor programs.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA
Redigert 11.04.2022 kl 07:18 Du må logge inn for å svare
StockWizard
11.04.2022 kl 07:08 6670

klaesp skrev Spennende 👍
Melding! 🤓
Yzf R1
11.04.2022 kl 07:13 7115

Ein ansettelse , jaja det kom ein melding det ska du ha 😂
BioBull
11.04.2022 kl 07:20 7104

Mer enn en ansettelse …

BerGenBio is stepping up their game 👍
Redigert 11.04.2022 kl 08:57 Du må logge inn for å svare
mimer
11.04.2022 kl 09:40 7125

Veldig fokus på AXL for ny CMO. Er det hun som skal bringe bem over mållinja og få med BP til fase 3?!
Predator
11.04.2022 kl 10:34 7011

Dette minner sterkt om utviklingen som dro Photocure fra 40.- til 150.- Nesten som en blåkopi vil jeg si, og jeg var med hele veien.
BioBull
12.04.2022 kl 12:00 6790

👍 : A Predators best weapon is patience 👏👏👏
tomcat66
13.04.2022 kl 10:09 11746

Robothandler og meglere herjer igjen....
Arrowstreet siste shortbet sørger for å holde den igjen. En får heller nyte påsken, holde på aksjene og vente på gode nyheter som vil komme.
BioBull
13.04.2022 kl 23:59 11534



Same short shit criminals - new wrapping …

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

CITADEL ADVISORS LLC
Gullit
22.04.2022 kl 06:42 10974

Spennende. Undrer på hvor Bergen bio ligger i løypen?
Forum forum
22.04.2022 kl 07:08 10936

Ja, men dette er jo en kjent behandling som allerede er beregnet i BergenBio analyse av behovet for en etterbehandling.
Denne må tas ila 3-5 dager etter smitte.

Jeg er vel så spent på Bemcentinib mot influensa. Tilbakemeldingene nå er at årets vaksine ikke gir god beskyttelse for svake og utsatte grupper.
klaesp
22.04.2022 kl 07:35 10885

Viktig poeng du kommer med her i første avsnitt, Forum forum. Bemcentintinib skal tas sent i sykdomsforløp
BioBull
25.04.2022 kl 07:45 10618

Fasten Seat Belts …. 👍


07:00 25.04.2022
BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022

Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that it is presenting data today from its Phase IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held both online and in-person in Lisbon, Portugal, from April 23-26, 2022.

The poster presentation will share findings from the Company’s Phase IIa open label study of 115 patients evaluating bemcentinib in combination with Standard of Care (SoC) compared to a SoC control arm in the treatment of moderate to severe COVID-19 patients, immediately after hospital admission (BGBC020).

Clinical data from the study show that bemcentinib treatment (up to 14 days) confers early and sustained protection, limiting clinical deterioration in patients. Bemcentinib treated patients were discharged earlier from the hospital, required less supplementary oxygen and demonstrated a significant reduction in the need for intubation or ventilation.

Biomarker analysis demonstrates that treatment with bemcentinib reduced markers of acute inflammation and profibrotic cytokines, and increased expression of protective factors. These changes were more pronounced in patients with more serious disease, determined by high C-Reactive Protein (CRP) rates, high neutrophil to lymphocyte ratio (N/L) ratio or increased oxygen usage.

Preclinical data is also being presented from in vitro studies in lung epithelial cells on bemcentinib’s activity on variants of concern. These data suggest that bemcentinib inhibits infection of multiple SARS-CoV-2 variants, including Omicron, building on previous preclinical research from the Company.


Martin Olin, CEO of BerGenBio, commented: “The data we are presenting at ECCMID today further demonstrates the effectiveness of bemcentinib as a treatment for severe respiratory infections such as COVID-19. We have been pleased to see bemcentinib’s impact on reducing disease deterioration in patients. In addition, we’re encouraged to see that bemcentinib exerts a broad anti-inflammatory and pro-repair effect on blood biomarkers. We look forward to the initiation of the EUSolidAct platform trial which will further assess bemcentinib in hospitalised COVID-19 patients.”

Details of today’s poster presentation are as follows:

Abstract: 04778: Bemcentinib modulation of inflammatory, fibrotic and tissue repair pathways correspond with favourable clinical outcomes in hospitalised COVID-19 patients demonstrating higher severity cues: a biomarker perspective

Session Name: 12c. Clinical features, case management, outcome (incl long-term): programme no. L0383

Time, Location: Monday, 25th April 2022, 12:00pm - 13:00pm (WEST)
Redigert 25.04.2022 kl 07:47 Du må logge inn for å svare
Gullit
25.04.2022 kl 08:31 10639

Ser meget lovende ut. Kan bli en viktig del av behandlingen mot flere varianter…
MiniMe
25.04.2022 kl 08:49 10712

Hvor lenge har selskapet igjen her på Oslo børs? Venter oppkjøp med mine aksjer.
AXL a promising target to treat life-threatening diseases!!!!!!!
ctrlaltdel
25.04.2022 kl 09:18 10682

Skuffende at EU ikke har kommet igang. Hvor mange år skal de bruke!
BioBull
25.04.2022 kl 12:09 10457

Alle som vil får spør på GF denne uka …,

Ellers bør ikke ledelsen få BGBIO opsjoner før de leverer fase III resultater som materialiserer seg i godkjente medisiner synes jeg… utvanning grunnet ingen nytte - de må gjerne få opsjoner - men disse må forfalle verdiløse når det ikke leveres resultater innen forventet tid.

Går aksjekursen opp må det etter forfall av opsjoner settes nye innløsnings kurs…

Ledelsens tyveri av gratis opsjoner inn i evigheten fremstår som et ran på åpen gate - godkjent av idiotiske hoved aksjonærer som forvalter andre penger.

Små aksjonærer foren dere og stem mot alle opsjons ordninger på Generalforsamlingen !
kongkveite
25.04.2022 kl 17:30 10169

Trøstesløs utvikling .. dette går bare ikke veien💸
Forum forum
25.04.2022 kl 17:51 10130

Sterk analyse der.
At selskapet vitenskapelig beviser at produktet deres er trygt og bedrer folks helse i løpet av en 14 dagers kur skal man ikke vektlegge spesielt.
Er sikker på at både influensa og Covid-19 blir borte av seg selv de neste ukene og aldri kommer tilbake.
ctrlaltdel
25.04.2022 kl 20:11 9987

Den vedder jeg imot
BioBull
26.04.2022 kl 07:03 9745




BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS – PRIMARY EFFICACY ENDPOINT MET

Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy

BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 patients

Bergen, Norway, April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced today that a complete data analysis of a randomized phase II study of bemcentinib in combination with standard of care (SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19 patients confirms that the primary efficacy endpoint was met.

At the July 2021 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) meeting, the Company previously presented preliminary data from the ACCORD2 study in combination with a second COVID-19 study (BGBC020) showing evidence of therapeutic benefit on meaningful clinical endpoints in a total of 177 patients. Today’s announcement is the first time complete ACCORD2 data in a total of 61 treated patients has been separately reported.

Overall, 90% of patients treated with bemcentinib + SoC (26 of 29) experienced a clinical response by day 29 (median 7.0 days), as defined by either a two-point improvement in World Health Organization (WHO) category from baseline score, or discharge from hospital, whichever arose sooner. This compared to 69% (22 of 32 patients) with a clinical response to SoC treatment alone (median 9.5 days), showing statistical significance.

The data was generated under a sub-protocol of the platform ACCORD2 study (ACCORD2; EudraCT 2020-001736-95 - BGBIL019), a multi-center phase II randomized study designed to assess the efficacy and safety of candidate agents as add-on therapies to SoC for the treatment of COVID-19 in hospitalized patients.

Overall, 98% of patients received dexamethasone or an equivalent steroid in their SoC, and 18% received immunomodulatory treatment with tocilizumab. The antiviral remdesivir was used in 53% of those randomized to SoC alone, and in 21% of patients treated with bemcentinib.

In addition, key secondary endpoints saw statistically significant improvements for the bemcentinib + SoC arm compared to SoC alone, including avoidance of any deterioration by ≥1-point increase in WHO score (including death) and ventilator-free survival over 29 days. At day 29, 97% of bemcentinib + SoC treated patients were alive compared to 81% of SoC-alone.

Bemcentinib treatment was well tolerated in this patient population, with no clinically relevant safety signals in comparison to standard of care treatment.

These latest results underline bemcentinib’s potential in COVID-19 and other severe respiratory infections. As previously announced, bemcentinib will be studied in the EU-SolidAct trial in up to 500 hospitalized COVID-19 patients.

Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS, Professor of Respiratory Medicine and Chief Investigator on the ACCORD program commented: "With COVID-19 still driving hospital admissions globally it is key that new, more effective treatments are being developed. These results from the ACCORD2 program indicate that bemcentinib has demonstrated real promise as a new therapeutic option for hospitalized patients and it now warrants testing in larger studies. These results are a testament to the great collaboration between the NHS, NIHR, the MEU and our Southampton research teams with more exciting results to follow from the platform."

Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are highly encouraged by the final data from our ACCORD2 study in hospitalized COVID-19 patients. The ability of bemcentinib to add a statistically significant benefit in clinical response over standard of care therapy is promising. We look forward to moving to the next step in the development of bemcentinib for COVID-19 through our participation in the EUSolidAct platform study, designed to enrol up to 500 hospitalized COVID-19 patients.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700


About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

About ACCORD2 study
Under the bemcentinib sub-protocol of the ACCORD2 study, patients were enrolled within a calendar day after being admitted to hospital. Eligible patients were categorized by the WHO 9-point clinical scale and ranged from patients who did not require supplementary oxygen (grade 3) to those requiring non-invasive ventilation or high-flow nasal oxygen, but not intubated (grade 5). In the bemcentinib sub-protocol 29 patients were randomized and received bemcentinib treatment in addition to SoC.
For further details: https://clinicaltrials.gov/ct2/show/NCT04890509


Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
BioBull
26.04.2022 kl 07:09 9737

ctrlaltdel skrev Den vedder jeg imot
Jeg vedder fortsatt på at BerGenBio aksjen går i 2500 før Jul - men ikke hvilken Jul…
klaesp
26.04.2022 kl 07:33 9684

Liker denne svært godt..

"Bergen, Norway, April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced today that a complete data analysis of a randomized phase II study of bemcentinib in combination with standard of care (SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19

patients confirms that the primary efficacy endpoint was met. "

Siste settningen 🎯
Gullit
26.04.2022 kl 07:39 9653

Dette var hinsides bra resultater… spent på hvor dette tar oss, burde se en dobling av kurs idag!!
GOV
26.04.2022 kl 08:00 9738

Nå har Finansavisen også tatt inn en artikkel:
" BerGenBio opplyser tirsdag at en fullstendig dataanalyse av en randomisert fase II-studie av bemcentinib i kombinasjon med standardbehandling (SoC), ACCORD2 (BGBIL019), hos innlagte covid-19-pasienter bekrefter at det primære effektendepunktet ble møtt.

På European Congress of Clinical Microbiology & Infectious møtet i juli 2021 presenterte selskapet foreløpige data fra ACCORD2-studien i kombinasjon med en covid-19-studie (BGBC020), som viste en terapeutisk fordel med meningsfulle kliniske endepunkter i totalt 177 pasienter.

I dag er det første gang komplette ACCORD2-data fra totalt 61 behandlede pasienter har blitt rapportert separat.

Totalt sett opplevde 90 prosent av pasientene behandlet med bemcentinib og SoC (26 av 29) en klinisk respons innen dag 29 (median 7 dager). Dette kan sammenlignes med 69 prosent (22 av 32 pasienter) med klinisk respons på SoC-behandling alene (median 9,5 dager), som viser statistisk signifikans."
Redigert 26.04.2022 kl 08:03 Du må logge inn for å svare
klaesp
26.04.2022 kl 08:12 10456

Fantastisk, litt kjedelig at denne kom nå og ikke under pandemi.. Men det kan blii svært bra på litt lengre sikt.
Gratulerer 🃏
Kajtek
26.04.2022 kl 08:17 10440

Pandemien er nok ikke over enda. Det er rett før Kina stenger alt ned igjen.
klaesp
26.04.2022 kl 08:19 10531

Enig👍
Hjelpalaus
26.04.2022 kl 08:20 10562

Ja, men Kina har ikke tenkt å bekjempe pandemien med medisiner. Der er det total lockdown som gjelder. Eventuelt sure blader og løvetannjuice. Fy faen for noen Idioter.
ctrlaltdel
26.04.2022 kl 08:20 10582

Trøkket på helsevesenet er større nå enn da den fjerde statsmakt hauset den såkalte who definerte pandemi. Nå er det krig, det er reelt.
tobo581
26.04.2022 kl 08:40 10739

Dette er veldig positivt.
Korona blir ikke borte og det er alltid en reell fare for ny oppblomstring. Sannsynligvis ikke i sommer som var tilsvarende i fjor, men det kommer.
mimer
26.04.2022 kl 11:47 10441

Er vel stort sett bare i Norge "folk flest" tror pandemien er over...det fortelles om rekordsmitte i Tyskland, og i Sverige forventer FMI mer enn dobling av antall dalig innlagte på sykehus framover, fra ca 25 / dag til 60.

Fler väntas läggas in på sjukhus efter ny omikronvariant
UPPDATERAD IDAG 09:22PUBLICERAD IGÅR 19:37

https://www.svt.se/nyheter/inrikes/experten-nastan-enbart-nya-varianten-ba-2-i-sverige
BioBull
27.04.2022 kl 14:11 9917

Generalforsamling 28.04.2022

Hvilke overraskelser kan vi forvente oss.

Et tilsvarende selskap i USA som har langt svakere pipeline enn BerGenBio er ZENTALIS.

Seldkapets verdi på Nasdaq er betydelig høyere enn BerGenBio. Nå går Pfizer inn med 25 mill USD i en rettet emisjon mot selskapet på ca 20 % høyere pris enn børskurs. Dette er 60-70% lavere enn topp notering fra tidligere.

Dersom ledelsen og styret gjør det samme vil det frarøve og vanne ut eksisterende aksjonærer i BerGenBio.

Jeg håper store og små aksjonærer vet hva dette innebærer.

Ledelsen og styret i selskapet bør derfor ikke få tillatelse til å utstede nye aksjer til selskap som f.eks Merck som er en naturlig samarbeids partner. Det er bedre å innhente fremmedkapItal dersom det er behov for arbeidskapital enn å selge aksjer til spottpris.

https://ir.zentalis.com/investor-relations/
kongkveite
27.04.2022 kl 15:08 9882

Liten interesse for aksjen siste året sier vel sitt.
Forventer at kursen gruses ytterligere og at vi ser ATL løpet av Mai.
Matadoren
27.04.2022 kl 15:41 9904

Utstede aksjer til BP til 20 % overkurs = ja takk, utstede aksjer til investorer til 10-20% rabatt = nei takk